SCHEMBL4856749

SCHEMBL4856749

CC(CCN)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
KEAP1 Q14145 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
GABBR2 O75899 1/20 0.35
GABBR1 Q9UBS5 1/20 0.35
DPP4 P27487 1/20 0.35
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SLC6A2 P23975 1/20 0.32
USP2 O75604 1/20 0.31
KCNA5 P22460 1/20 0.31
KDM1A O60341 1/20 0.31
AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7043086 0.88 KEAP1 (0.45) KMT2AMEN1KEAP1SMN1; SMN2LMNA
SCHEMBL27094636 0.84
SCHEMBL2385429 0.84
SCHEMBL39810 0.82 KMT2A (0.41) KMT2AMEN1KEAP1SMN1; SMN2LMNA
SCHEMBL2485265 0.82 KMT2A (0.41) KMT2AMEN1KEAP1SMN1; SMN2LMNA
SCHEMBL18660961 0.81 KMT2A (0.45) KMT2AMEN1LMNAALDH1A1GAA
SCHEMBL18660918 0.81 KMT2A (0.45) KMT2AMEN1LMNAALDH1A1GAA
SCHEMBL24736445 0.80 KMT2A (0.47) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL232222 0.80 KMT2A (0.47) KMT2AMEN1LMNAALDH1A1GAA
SCHEMBL8737569 0.80 KMT2A (0.47) KMT2AMEN1LMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462613-B2 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-12-09 US disclosed
US-20070261720-A1 Voc Free Coatings Strippers VOCFREE, INC. 2007-11-15 US disclosed
EP-1611121-B1 PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS AVENTIS PHARMA SA (FR) 2007-08-08 EP disclosed
EP-1581505-B1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-01 EP disclosed
US-20070167490-A1 Imino ether derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO LTD 2007-07-19 US disclosed
EP-1602642-A1 IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2005-12-07 EP disclosed
US-20050026918-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-02-03 US disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167490-A1 Imino ether derivative compounds and drugs containing the compounds as the active ingredient INSR, NR1H2, NR1H3 KMT2A 2306/4885MEN1 2650/4885KEAP1 1999/4885
US-20050026918-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them C5, ADRA2C, ADRA1A KMT2A 3061/4885MEN1 997/4885KEAP1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.